1. Home
  2. PMI vs GNPX Comparison

PMI vs GNPX Comparison

Compare PMI & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PMI

Picard Medical Inc.

HOLD

Current Price

$0.13

Market Cap

14.1M

Sector

N/A

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.81

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMI
GNPX
Founded
1981
2009
Country
United States
United States
Employees
75
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.1M
11.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PMI
GNPX
Price
$0.13
$0.81
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.1M
324.2K
Earning Date
06-18-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.14
52 Week High
$13.68
$12.97

Technical Indicators

Market Signals
Indicator
PMI
GNPX
Relative Strength Index (RSI) 17.57 33.09
Support Level N/A $0.74
Resistance Level $0.27 $2.12
Average True Range (ATR) 0.03 0.04
MACD 0.02 0.02
Stochastic Oscillator 16.11 44.17

Price Performance

Historical Comparison
PMI
GNPX

About PMI Picard Medical Inc.

Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: